Persantine: Variation in Response Trial

• Status: Terminated
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to understand why different people respond differently to the medication Persantine. The effects of Persantine will be evaluated by performing echocardiograms, blood tests and by measuring the flow of blood in the arteries of the heart in patients undergoing a clinically indicated percutaneous coronary intervention.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UConn Health
• Collaborator: United States Department of Defense
• Treatments: Dipyridamole

Criteria

Inclusion Criteria:

• Patients > 21 years old

• Patient undergoing cardiac catheterization with planned PTCA or with a significant coronary lesion of either the LAD or Circumflex

Exclusion Criteria:

• Theophylline or oral Persantine use in 24hrs

• Second or third degree AV block, or sick sinus syndrome without a functioning pacemaker

• Active asthma or bronchospasm

• Patients with severe hepatic insufficiency

• Patients experiencing an acute transmural infarction at the time of the index visit

• Conditions that are known to affect resistive vessel function or myocardial flow